Polaryx Therapeutics, Inc. G&A increased by 280.7% to $1.28M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Rising G&A as a percentage of revenue may indicate organizational bloat, while stability suggests effective cost management.
General and administrative expenses cover the overhead costs of running the business, including executive salaries, lega...
Standard operating expense category; used to assess administrative leverage.
general_and_administrative| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $336.00K | $1.28M |
| QoQ Change | — | +280.7% |
| YoY Change | — | +280.7% |
| Segment | Q1 '25 | Q1 '26 |
|---|---|---|
| Lysosomal Storage Disorders | $229.00K | $812.00K |
| Total | $336.00K | $1.28M |